ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
TUESDAY, June 6, 2023 (HealthDay News) — For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study pub…
Learn MoreASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer
THURSDAY, June 1, 2023 (HealthDay News) — For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progression-free survival, accor…
Learn MoreUna vacuna ralentiza la recurrencia del cáncer de páncreas en un ensayo inicial
JUEVES, 11 de mayo de 2023 (HealthDay News) — Una vacuna personalizada, dirigida a los genes, podría retrasar la recurrencia del cáncer de páncreas, según un ensayo de tamaño reducido, pero promisorio. La vacuna de ARNm, que se adaptó a la genética d…
Learn MoreVaccine Slows Return of Pancreatic Cancer in Early Trial
THURSDAY, May 11, 2023 (HealthDay News) – A gene-targeted personalized vaccine may delay the return of pancreatic cancer according to a small, but promising, trial.The mRNA vaccine, which was tailored to the genetic makeup of each patient’s tumor, wor…
Learn MoreImmunotherapy Works Well for Young Children With Peanut Allergy
WEDNESDAY, May 10, 2023 (HealthDay News) — For children aged 1 to 3 years with peanut allergy, epicutaneous immunotherapy for 12 months is superior for desensitizing children to peanuts, according to a study published in the May 11 issue of the New E…
Learn MoreCemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
WEDNESDAY, May 10, 2023 (HealthDay News) — Cemiplimab plus chemotherapy results in significant overall improvement in pain symptoms and delayed deterioration in cancer-related and lung cancer-specific symptoms and functions, according to a study publ…
Learn MoreExercise May Boost Tumor-Fighting Immune Cells in Cancer Patients
FRIDAY, May 5, 2023 (HealthDay News) — Cancer patients have a lot to think about, but adding one more thing — lacing up their sneakers — may pay off.Two new studies suggest engaging in light or moderate exercise increases the number of cancer-destr…
Learn MorePatient-Centered Approach Recommended for Oligometastatic NSCLC
TUESDAY, May 2, 2023 (HealthDay News) — A patient-centered, multidisciplinary approach is strongly recommended for decision-making regarding treatment for oligometastatic non-small cell lung cancer (NSCLC), according to a clinical practice guideline …
Learn MoreAACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
MONDAY, May 1, 2023 (HealthDay News) — For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free survival (EFS), according to a study p…
Learn MoreRacial, Ethnic Disparities Seen for Subcutaneous Allergen Immunotherapy
FRIDAY, April 28, 2023 (HealthDay News) – Racial and ethnic disparities exist in the initiation of subcutaneous allergen immunotherapy (SCIT) among patients with allergic rhinitis (AR), according to a study recently published in the Journal of Allergy…
Learn More